Myo-Inositol in Pregnancy: Implications for Acne Management

Area of Science:

• Dermatology
• Endocrinology
• Obstetrics

Background:

• Acne vulgaris commonly occurs during pregnancy, posing treatment challenges due to medication restrictions and fetal safety concerns.
• There is a need for safe adjunctive therapies targeting hormonal and metabolic factors contributing to pregnancy acne.
• Myo-inositol is explored as a potential solution due to its safety profile.

Purpose of the Study:

• To evaluate the efficacy of myo-inositol as an adjunctive treatment for acne during pregnancy.
• To analyze its relevance in managing associated metabolic, endocrine, and psychosocial conditions.
• To contextualize its use within dermatologic care.

Main Methods:

• A comprehensive literature review was performed.
• Included studies encompassed randomized controlled trials, systematic reviews, meta-analyses, observational studies, and mechanistic investigations.
• The review focused on myo-inositol's effects on acne, PCOS, GDM, preeclampsia, fertility, mood, sleep, and topical applications.

Main Results:

• Myo-inositol supplementation correlated with reduced acne severity, particularly in PCOS patients, and improved insulin sensitivity.
• In pregnancy, it was linked to lower GDM incidence, better metabolic markers for preeclampsia, and enhanced reproductive outcomes.
• Benefits for mood and sleep were also noted, with a favorable maternal and fetal safety profile.

Conclusions:

• Myo-inositol presents a potentially safe adjunctive treatment for pregnancy-related acne, especially in individuals with metabolic or hyperandrogenic features.
• While direct acne-specific pregnancy data are limited, existing evidence supports its consideration in dermatologic practice.
• Its safety profile and benefits for associated conditions make it a relevant option when conventional treatments are restricted.